Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preference study of Mecapegfilgrastim Injection vs Auto-Mecapegfilgrastim on‑body injector in chemotherapy-treated cancer patients
CTR20240218Phase 3Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of mecapegfilgrastim in chemotherapy-induced neutropenia (CIN), febrile neutropenia (FN), sponsored by Hengrui Therapeutics. Started Jan 2024; status: terminated.
02
Drugs
mecapegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)febrile neutropenia (FN)
Beyond the preview
Go deeper on CTR20240218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240218.